The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all five indications across various hematological cancers.MLD has a considerable effect on the social, emotional and Qualified life of patients and their households, like a median of seventeen hrs on a daily basis spent by families caring for their kid with MLD.8“MLD is